SoliMix结果公布:基础胰岛素与GLP-1RA的复方制剂与预混胰岛素的头对头比较研究

2021-07-05 ADA年会 ADA年会

随着新技术、新疗法及相关循证证据的不断涌现,近年来糖尿病治疗日新月异。 对糖尿病患者而言,血糖监测是实现血糖控制达标的重要手段之一。 对于2型糖尿病的药物治疗,多项指南再次强调了以患者为中心指导药物的

在胰岛素百年诞辰之际,第81届ADA(美国糖尿病学会)年会的召开为科学界提供了一个回顾和庆祝糖尿病治疗百年进步,思考和展望胰岛素未来发展的机会。

随着新技术、新疗法及相关循证证据的不断涌现,近年来糖尿病治疗日新月异。 对糖尿病患者而言,血糖监测是实现血糖控制达标的重要手段之一。 对于2型糖尿病的药物治疗,多项指南再次强调了以患者为中心指导药物的选择。

值得关注的是,在此次ADA年会上,全球首个对比基础胰岛素和胰高血糖素样受体激动剂的复方制剂(iGlarLixi)与预混胰岛素的头对头研究——SoliMix结果公布。

SoliMix研究纳入了基础胰岛素联合1~2种口服降糖药治疗,血糖控制不佳的2型糖尿病(T2DM)患者,并将其分为基础胰岛素GLP-1RA复方制剂(甘精胰岛素与利司那肽固定比例复方制剂,iGlarLixi)治疗组与预混胰岛素(双相门冬胰岛素30,BIAsp 30)治疗组,而后研究者对研究的两个主要研究终点和多个关键次要研究终点进行了头对头比较。该项研究结果除在第81届ADA年会上发布外,也将同步发表于Diabetes Care杂志。

1. SoliMix研究证实,与预混胰岛素相比,iGlarLixi在降低糖化血红蛋白(HbA1c)水平方面具有非劣效性,同时在体重影响方面具有优效性(主要研究终点)。


2. SoliMix研究也证实,与预混胰岛素相比,iGlarLixi治疗的患者血糖达标(HbA1c<7%)且体重不增加的比例更高;血糖达标、体重不增加且不发生低血糖的患者比例也更高;此外,iGlarLixi治疗相对预混胰岛素降低HbA1c具有优效性(次要研究终点)。

SoliMix研究主要作者、德克萨斯州达拉斯市医学城达拉斯糖尿病研究中心主任—Julio Rosenstock 表示:“对低血糖和体重增加的担忧是推进复杂胰岛素治疗方案的主要障碍。SoliMix研究表明,与BIAsp 30相比,iGlarLixi治疗在不增加体重和未发生低血糖的情况下,可改善患者的血糖控制情况。这种多重获益可以帮助临床医生考虑通过转换为每日一次iGlarLixi治疗的方式来继续推进基础胰岛素治疗方案,而不是转换为每日两次的预混胰岛素治疗。”

SoliMix研究的另一分析结果还发现,iGlarLixi与预混胰岛素相比,在第26周时,其对患者报告结局也有了更大程度的改善。其中患者报告结局通过治疗相关的影响测评-糖尿病(TRIM-D)和患者-医生对整体治疗效果评估(GTEE)的分值来衡量,其测量工具涵盖了治疗负担、日常生活、糖尿病管理、依从性、心理健康以及治疗效果多个维度。

1. TRIM-D结果显示,与使用预混胰岛素的患者相比,使用iGlarLixi治疗的患者在依从性、糖尿病管理和心理健康等方面有更大程度的改善。

2. GTEE结果显示,使用iGlarLixi治疗后,患者报告糖尿病完全控制率约为预混胰岛素治疗组的2倍,同样,iGlarLixi治疗组中报告患者糖尿病完全控制的医生比例也约为预混胰岛素治疗组的2倍。

赛诺菲普药全球医疗负责人Sandra Silvestri博士表示:“目前全球仍有约40%的患者使用预混胰岛素来控制T2DM。而SoliMix揭示了iGlarLixi疗效以及患者报告结局等更多信息,该项研究结果的发布,可以为广泛使用预混胰岛素治疗的国家地区的医疗机构提供一种新的治疗选择。”

赛诺菲大中华区普药医学部负责人谷成明博士表示:“中国拥有约1.298亿糖尿病患者,排名全球第一,同时随着中国医疗水平的整体提升,糖尿病临床诊断和治疗理念也在不断进步,因此中国糖尿病领域尚存在巨大的未被满足的需求。此次SoliMix研究结果的发布也为中国糖尿病患者带来了新的期待。赛诺菲始终秉承对中国患者的承诺,未来我们将持续丰富糖尿病领域在中国的产品线,为中国糖尿病患者带来更多创新的治疗方案。”

*iGlarLixi是一种注射类降糖药,由甘精胰岛素100U/mL与利司那肽按固定比例组合而成。iGlarLixi尚未在中国获批。iGlarLixi在欧盟被称为“Suliqua®”,Suliqua®可用于联合生活方式管理及二甲双胍或二甲双胍和SGLT2抑制剂,改善成人T2DM患者的血糖控制情况 ;iGlarLixi在美国被称为“Soliqua®100/33”,可联合生活方式管理用于改善成人T2DM患者的血糖控制情况;在其他获批地区,iGlarLixi也被称为“Soliqua®”。

参考文献:
1. Rosenstock, J., et al. “Advancing Therapy in Uncontrolled Basal Insulin-Treated Type 2 Diabetes (T2D): Better Clinical Outcomes with iGlarLixi vs Premix 70/30 in the SoliMix Trial”, Presentation 234-OR, American Diabetes Association (ADA) 81st Scientific Sessions (virtual event), June 28, 2021. 
2. Rosenstock, J., et al. Advancing therapy in suboptimally controlled basal insulin-treated type 2 diabetes: Clinical outcomes with iGlarLixi versus premix BIAsp 30 in the SoliMix randomized controlled trial. Diabetes Care. 2021 Jun 28.
3. Polonsky, W., et al. “Improved Treatment Perceptions with iGlarLixi vs Premix Insulin in Type 2 Diabetes (T2D) Uncontrolled on Basal Insulin (BI) + Oral Antihyperglycemic Drugs (OADs): Patient-reported Outcomes (PROs) of the SoliMix Trial”, Presentation 747-P, American Diabetes Association (ADA) 81st Scientific Sessions (virtual event), June 28, 2021. 
4. Yongze Li, Di Teng, Xiaoguang Shi, et al., Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study. BMJ, 2020. 369: p. m997.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1658670, encodeId=5f5616586e09f, content=<a href='/topic/show?id=4b4d80e878' target=_blank style='color:#2F92EE;'>#GLP-1R#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8078, encryptionId=4b4d80e878, topicName=GLP-1R)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fea024898996, createdName=360611848, createdTime=Tue Dec 28 01:18:39 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1750233, encodeId=d68b1e502336d, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Fri Dec 17 22:18:39 CST 2021, time=2021-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949827, encodeId=55b2194982eb3, content=<a href='/topic/show?id=92ed443582b' target=_blank style='color:#2F92EE;'>#头对头#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44358, encryptionId=92ed443582b, topicName=头对头)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Fri Mar 04 23:18:39 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004437, encodeId=f6dd200443ead, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78621, encryptionId=54ebe8621cf, topicName=结果公布)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Mon Sep 13 11:18:39 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422759, encodeId=3d0e1422e593d, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8077, encryptionId=54fa80e701, topicName=GLP-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8f23732777, createdName=yibei, createdTime=Thu Jul 01 08:18:39 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587142, encodeId=c7b6158e14200, content=<a href='/topic/show?id=a8fd10024527' target=_blank style='color:#2F92EE;'>#预混胰岛素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100245, encryptionId=a8fd10024527, topicName=预混胰岛素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2da517440382, createdName=xjy08, createdTime=Thu Jul 01 08:18:39 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601062, encodeId=7a4916010621b, content=<a href='/topic/show?id=dd43426460c' target=_blank style='color:#2F92EE;'>#复方制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42646, encryptionId=dd43426460c, topicName=复方制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=279318829047, createdName=chengjn, createdTime=Thu Jul 01 08:18:39 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622007, encodeId=c41d162200e2b, content=<a href='/topic/show?id=392480e970' target=_blank style='color:#2F92EE;'>#GLP-1RA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8079, encryptionId=392480e970, topicName=GLP-1RA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Jul 01 08:18:39 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623085, encodeId=36ad16230859a, content=<a href='/topic/show?id=2eb542152f0' target=_blank style='color:#2F92EE;'>#基础胰岛素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42152, encryptionId=2eb542152f0, topicName=基础胰岛素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51af20470990, createdName=liuyong2987, createdTime=Thu Jul 01 08:18:39 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978073, encodeId=85a19e80733e, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df324723890, createdName=452946589, createdTime=Tue Jun 29 23:48:57 CST 2021, time=2021-06-29, status=1, ipAttribution=)]
    2021-12-28 360611848
  2. [GetPortalCommentsPageByObjectIdResponse(id=1658670, encodeId=5f5616586e09f, content=<a href='/topic/show?id=4b4d80e878' target=_blank style='color:#2F92EE;'>#GLP-1R#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8078, encryptionId=4b4d80e878, topicName=GLP-1R)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fea024898996, createdName=360611848, createdTime=Tue Dec 28 01:18:39 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1750233, encodeId=d68b1e502336d, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Fri Dec 17 22:18:39 CST 2021, time=2021-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949827, encodeId=55b2194982eb3, content=<a href='/topic/show?id=92ed443582b' target=_blank style='color:#2F92EE;'>#头对头#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44358, encryptionId=92ed443582b, topicName=头对头)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Fri Mar 04 23:18:39 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004437, encodeId=f6dd200443ead, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78621, encryptionId=54ebe8621cf, topicName=结果公布)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Mon Sep 13 11:18:39 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422759, encodeId=3d0e1422e593d, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8077, encryptionId=54fa80e701, topicName=GLP-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8f23732777, createdName=yibei, createdTime=Thu Jul 01 08:18:39 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587142, encodeId=c7b6158e14200, content=<a href='/topic/show?id=a8fd10024527' target=_blank style='color:#2F92EE;'>#预混胰岛素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100245, encryptionId=a8fd10024527, topicName=预混胰岛素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2da517440382, createdName=xjy08, createdTime=Thu Jul 01 08:18:39 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601062, encodeId=7a4916010621b, content=<a href='/topic/show?id=dd43426460c' target=_blank style='color:#2F92EE;'>#复方制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42646, encryptionId=dd43426460c, topicName=复方制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=279318829047, createdName=chengjn, createdTime=Thu Jul 01 08:18:39 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622007, encodeId=c41d162200e2b, content=<a href='/topic/show?id=392480e970' target=_blank style='color:#2F92EE;'>#GLP-1RA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8079, encryptionId=392480e970, topicName=GLP-1RA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Jul 01 08:18:39 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623085, encodeId=36ad16230859a, content=<a href='/topic/show?id=2eb542152f0' target=_blank style='color:#2F92EE;'>#基础胰岛素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42152, encryptionId=2eb542152f0, topicName=基础胰岛素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51af20470990, createdName=liuyong2987, createdTime=Thu Jul 01 08:18:39 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978073, encodeId=85a19e80733e, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df324723890, createdName=452946589, createdTime=Tue Jun 29 23:48:57 CST 2021, time=2021-06-29, status=1, ipAttribution=)]
    2021-12-17 baoya
  3. [GetPortalCommentsPageByObjectIdResponse(id=1658670, encodeId=5f5616586e09f, content=<a href='/topic/show?id=4b4d80e878' target=_blank style='color:#2F92EE;'>#GLP-1R#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8078, encryptionId=4b4d80e878, topicName=GLP-1R)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fea024898996, createdName=360611848, createdTime=Tue Dec 28 01:18:39 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1750233, encodeId=d68b1e502336d, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Fri Dec 17 22:18:39 CST 2021, time=2021-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949827, encodeId=55b2194982eb3, content=<a href='/topic/show?id=92ed443582b' target=_blank style='color:#2F92EE;'>#头对头#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44358, encryptionId=92ed443582b, topicName=头对头)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Fri Mar 04 23:18:39 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004437, encodeId=f6dd200443ead, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78621, encryptionId=54ebe8621cf, topicName=结果公布)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Mon Sep 13 11:18:39 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422759, encodeId=3d0e1422e593d, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8077, encryptionId=54fa80e701, topicName=GLP-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8f23732777, createdName=yibei, createdTime=Thu Jul 01 08:18:39 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587142, encodeId=c7b6158e14200, content=<a href='/topic/show?id=a8fd10024527' target=_blank style='color:#2F92EE;'>#预混胰岛素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100245, encryptionId=a8fd10024527, topicName=预混胰岛素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2da517440382, createdName=xjy08, createdTime=Thu Jul 01 08:18:39 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601062, encodeId=7a4916010621b, content=<a href='/topic/show?id=dd43426460c' target=_blank style='color:#2F92EE;'>#复方制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42646, encryptionId=dd43426460c, topicName=复方制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=279318829047, createdName=chengjn, createdTime=Thu Jul 01 08:18:39 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622007, encodeId=c41d162200e2b, content=<a href='/topic/show?id=392480e970' target=_blank style='color:#2F92EE;'>#GLP-1RA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8079, encryptionId=392480e970, topicName=GLP-1RA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Jul 01 08:18:39 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623085, encodeId=36ad16230859a, content=<a href='/topic/show?id=2eb542152f0' target=_blank style='color:#2F92EE;'>#基础胰岛素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42152, encryptionId=2eb542152f0, topicName=基础胰岛素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51af20470990, createdName=liuyong2987, createdTime=Thu Jul 01 08:18:39 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978073, encodeId=85a19e80733e, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df324723890, createdName=452946589, createdTime=Tue Jun 29 23:48:57 CST 2021, time=2021-06-29, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1658670, encodeId=5f5616586e09f, content=<a href='/topic/show?id=4b4d80e878' target=_blank style='color:#2F92EE;'>#GLP-1R#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8078, encryptionId=4b4d80e878, topicName=GLP-1R)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fea024898996, createdName=360611848, createdTime=Tue Dec 28 01:18:39 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1750233, encodeId=d68b1e502336d, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Fri Dec 17 22:18:39 CST 2021, time=2021-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949827, encodeId=55b2194982eb3, content=<a href='/topic/show?id=92ed443582b' target=_blank style='color:#2F92EE;'>#头对头#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44358, encryptionId=92ed443582b, topicName=头对头)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Fri Mar 04 23:18:39 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004437, encodeId=f6dd200443ead, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78621, encryptionId=54ebe8621cf, topicName=结果公布)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Mon Sep 13 11:18:39 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422759, encodeId=3d0e1422e593d, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8077, encryptionId=54fa80e701, topicName=GLP-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8f23732777, createdName=yibei, createdTime=Thu Jul 01 08:18:39 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587142, encodeId=c7b6158e14200, content=<a href='/topic/show?id=a8fd10024527' target=_blank style='color:#2F92EE;'>#预混胰岛素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100245, encryptionId=a8fd10024527, topicName=预混胰岛素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2da517440382, createdName=xjy08, createdTime=Thu Jul 01 08:18:39 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601062, encodeId=7a4916010621b, content=<a href='/topic/show?id=dd43426460c' target=_blank style='color:#2F92EE;'>#复方制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42646, encryptionId=dd43426460c, topicName=复方制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=279318829047, createdName=chengjn, createdTime=Thu Jul 01 08:18:39 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622007, encodeId=c41d162200e2b, content=<a href='/topic/show?id=392480e970' target=_blank style='color:#2F92EE;'>#GLP-1RA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8079, encryptionId=392480e970, topicName=GLP-1RA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Jul 01 08:18:39 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623085, encodeId=36ad16230859a, content=<a href='/topic/show?id=2eb542152f0' target=_blank style='color:#2F92EE;'>#基础胰岛素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42152, encryptionId=2eb542152f0, topicName=基础胰岛素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51af20470990, createdName=liuyong2987, createdTime=Thu Jul 01 08:18:39 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978073, encodeId=85a19e80733e, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df324723890, createdName=452946589, createdTime=Tue Jun 29 23:48:57 CST 2021, time=2021-06-29, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1658670, encodeId=5f5616586e09f, content=<a href='/topic/show?id=4b4d80e878' target=_blank style='color:#2F92EE;'>#GLP-1R#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8078, encryptionId=4b4d80e878, topicName=GLP-1R)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fea024898996, createdName=360611848, createdTime=Tue Dec 28 01:18:39 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1750233, encodeId=d68b1e502336d, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Fri Dec 17 22:18:39 CST 2021, time=2021-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949827, encodeId=55b2194982eb3, content=<a href='/topic/show?id=92ed443582b' target=_blank style='color:#2F92EE;'>#头对头#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44358, encryptionId=92ed443582b, topicName=头对头)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Fri Mar 04 23:18:39 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004437, encodeId=f6dd200443ead, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78621, encryptionId=54ebe8621cf, topicName=结果公布)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Mon Sep 13 11:18:39 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422759, encodeId=3d0e1422e593d, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8077, encryptionId=54fa80e701, topicName=GLP-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8f23732777, createdName=yibei, createdTime=Thu Jul 01 08:18:39 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587142, encodeId=c7b6158e14200, content=<a href='/topic/show?id=a8fd10024527' target=_blank style='color:#2F92EE;'>#预混胰岛素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100245, encryptionId=a8fd10024527, topicName=预混胰岛素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2da517440382, createdName=xjy08, createdTime=Thu Jul 01 08:18:39 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601062, encodeId=7a4916010621b, content=<a href='/topic/show?id=dd43426460c' target=_blank style='color:#2F92EE;'>#复方制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42646, encryptionId=dd43426460c, topicName=复方制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=279318829047, createdName=chengjn, createdTime=Thu Jul 01 08:18:39 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622007, encodeId=c41d162200e2b, content=<a href='/topic/show?id=392480e970' target=_blank style='color:#2F92EE;'>#GLP-1RA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8079, encryptionId=392480e970, topicName=GLP-1RA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Jul 01 08:18:39 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623085, encodeId=36ad16230859a, content=<a href='/topic/show?id=2eb542152f0' target=_blank style='color:#2F92EE;'>#基础胰岛素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42152, encryptionId=2eb542152f0, topicName=基础胰岛素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51af20470990, createdName=liuyong2987, createdTime=Thu Jul 01 08:18:39 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978073, encodeId=85a19e80733e, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df324723890, createdName=452946589, createdTime=Tue Jun 29 23:48:57 CST 2021, time=2021-06-29, status=1, ipAttribution=)]
    2021-07-01 yibei
  6. [GetPortalCommentsPageByObjectIdResponse(id=1658670, encodeId=5f5616586e09f, content=<a href='/topic/show?id=4b4d80e878' target=_blank style='color:#2F92EE;'>#GLP-1R#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8078, encryptionId=4b4d80e878, topicName=GLP-1R)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fea024898996, createdName=360611848, createdTime=Tue Dec 28 01:18:39 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1750233, encodeId=d68b1e502336d, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Fri Dec 17 22:18:39 CST 2021, time=2021-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949827, encodeId=55b2194982eb3, content=<a href='/topic/show?id=92ed443582b' target=_blank style='color:#2F92EE;'>#头对头#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44358, encryptionId=92ed443582b, topicName=头对头)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Fri Mar 04 23:18:39 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004437, encodeId=f6dd200443ead, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78621, encryptionId=54ebe8621cf, topicName=结果公布)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Mon Sep 13 11:18:39 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422759, encodeId=3d0e1422e593d, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8077, encryptionId=54fa80e701, topicName=GLP-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8f23732777, createdName=yibei, createdTime=Thu Jul 01 08:18:39 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587142, encodeId=c7b6158e14200, content=<a href='/topic/show?id=a8fd10024527' target=_blank style='color:#2F92EE;'>#预混胰岛素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100245, encryptionId=a8fd10024527, topicName=预混胰岛素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2da517440382, createdName=xjy08, createdTime=Thu Jul 01 08:18:39 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601062, encodeId=7a4916010621b, content=<a href='/topic/show?id=dd43426460c' target=_blank style='color:#2F92EE;'>#复方制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42646, encryptionId=dd43426460c, topicName=复方制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=279318829047, createdName=chengjn, createdTime=Thu Jul 01 08:18:39 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622007, encodeId=c41d162200e2b, content=<a href='/topic/show?id=392480e970' target=_blank style='color:#2F92EE;'>#GLP-1RA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8079, encryptionId=392480e970, topicName=GLP-1RA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Jul 01 08:18:39 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623085, encodeId=36ad16230859a, content=<a href='/topic/show?id=2eb542152f0' target=_blank style='color:#2F92EE;'>#基础胰岛素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42152, encryptionId=2eb542152f0, topicName=基础胰岛素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51af20470990, createdName=liuyong2987, createdTime=Thu Jul 01 08:18:39 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978073, encodeId=85a19e80733e, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df324723890, createdName=452946589, createdTime=Tue Jun 29 23:48:57 CST 2021, time=2021-06-29, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1658670, encodeId=5f5616586e09f, content=<a href='/topic/show?id=4b4d80e878' target=_blank style='color:#2F92EE;'>#GLP-1R#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8078, encryptionId=4b4d80e878, topicName=GLP-1R)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fea024898996, createdName=360611848, createdTime=Tue Dec 28 01:18:39 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1750233, encodeId=d68b1e502336d, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Fri Dec 17 22:18:39 CST 2021, time=2021-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949827, encodeId=55b2194982eb3, content=<a href='/topic/show?id=92ed443582b' target=_blank style='color:#2F92EE;'>#头对头#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44358, encryptionId=92ed443582b, topicName=头对头)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Fri Mar 04 23:18:39 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004437, encodeId=f6dd200443ead, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78621, encryptionId=54ebe8621cf, topicName=结果公布)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Mon Sep 13 11:18:39 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422759, encodeId=3d0e1422e593d, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8077, encryptionId=54fa80e701, topicName=GLP-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8f23732777, createdName=yibei, createdTime=Thu Jul 01 08:18:39 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587142, encodeId=c7b6158e14200, content=<a href='/topic/show?id=a8fd10024527' target=_blank style='color:#2F92EE;'>#预混胰岛素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100245, encryptionId=a8fd10024527, topicName=预混胰岛素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2da517440382, createdName=xjy08, createdTime=Thu Jul 01 08:18:39 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601062, encodeId=7a4916010621b, content=<a href='/topic/show?id=dd43426460c' target=_blank style='color:#2F92EE;'>#复方制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42646, encryptionId=dd43426460c, topicName=复方制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=279318829047, createdName=chengjn, createdTime=Thu Jul 01 08:18:39 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622007, encodeId=c41d162200e2b, content=<a href='/topic/show?id=392480e970' target=_blank style='color:#2F92EE;'>#GLP-1RA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8079, encryptionId=392480e970, topicName=GLP-1RA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Jul 01 08:18:39 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623085, encodeId=36ad16230859a, content=<a href='/topic/show?id=2eb542152f0' target=_blank style='color:#2F92EE;'>#基础胰岛素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42152, encryptionId=2eb542152f0, topicName=基础胰岛素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51af20470990, createdName=liuyong2987, createdTime=Thu Jul 01 08:18:39 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978073, encodeId=85a19e80733e, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df324723890, createdName=452946589, createdTime=Tue Jun 29 23:48:57 CST 2021, time=2021-06-29, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1658670, encodeId=5f5616586e09f, content=<a href='/topic/show?id=4b4d80e878' target=_blank style='color:#2F92EE;'>#GLP-1R#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8078, encryptionId=4b4d80e878, topicName=GLP-1R)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fea024898996, createdName=360611848, createdTime=Tue Dec 28 01:18:39 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1750233, encodeId=d68b1e502336d, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Fri Dec 17 22:18:39 CST 2021, time=2021-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949827, encodeId=55b2194982eb3, content=<a href='/topic/show?id=92ed443582b' target=_blank style='color:#2F92EE;'>#头对头#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44358, encryptionId=92ed443582b, topicName=头对头)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Fri Mar 04 23:18:39 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004437, encodeId=f6dd200443ead, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78621, encryptionId=54ebe8621cf, topicName=结果公布)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Mon Sep 13 11:18:39 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422759, encodeId=3d0e1422e593d, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8077, encryptionId=54fa80e701, topicName=GLP-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8f23732777, createdName=yibei, createdTime=Thu Jul 01 08:18:39 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587142, encodeId=c7b6158e14200, content=<a href='/topic/show?id=a8fd10024527' target=_blank style='color:#2F92EE;'>#预混胰岛素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100245, encryptionId=a8fd10024527, topicName=预混胰岛素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2da517440382, createdName=xjy08, createdTime=Thu Jul 01 08:18:39 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601062, encodeId=7a4916010621b, content=<a href='/topic/show?id=dd43426460c' target=_blank style='color:#2F92EE;'>#复方制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42646, encryptionId=dd43426460c, topicName=复方制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=279318829047, createdName=chengjn, createdTime=Thu Jul 01 08:18:39 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622007, encodeId=c41d162200e2b, content=<a href='/topic/show?id=392480e970' target=_blank style='color:#2F92EE;'>#GLP-1RA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8079, encryptionId=392480e970, topicName=GLP-1RA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Jul 01 08:18:39 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623085, encodeId=36ad16230859a, content=<a href='/topic/show?id=2eb542152f0' target=_blank style='color:#2F92EE;'>#基础胰岛素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42152, encryptionId=2eb542152f0, topicName=基础胰岛素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51af20470990, createdName=liuyong2987, createdTime=Thu Jul 01 08:18:39 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978073, encodeId=85a19e80733e, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df324723890, createdName=452946589, createdTime=Tue Jun 29 23:48:57 CST 2021, time=2021-06-29, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1658670, encodeId=5f5616586e09f, content=<a href='/topic/show?id=4b4d80e878' target=_blank style='color:#2F92EE;'>#GLP-1R#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8078, encryptionId=4b4d80e878, topicName=GLP-1R)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fea024898996, createdName=360611848, createdTime=Tue Dec 28 01:18:39 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1750233, encodeId=d68b1e502336d, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Fri Dec 17 22:18:39 CST 2021, time=2021-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949827, encodeId=55b2194982eb3, content=<a href='/topic/show?id=92ed443582b' target=_blank style='color:#2F92EE;'>#头对头#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44358, encryptionId=92ed443582b, topicName=头对头)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Fri Mar 04 23:18:39 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004437, encodeId=f6dd200443ead, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78621, encryptionId=54ebe8621cf, topicName=结果公布)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Mon Sep 13 11:18:39 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422759, encodeId=3d0e1422e593d, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8077, encryptionId=54fa80e701, topicName=GLP-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8f23732777, createdName=yibei, createdTime=Thu Jul 01 08:18:39 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587142, encodeId=c7b6158e14200, content=<a href='/topic/show?id=a8fd10024527' target=_blank style='color:#2F92EE;'>#预混胰岛素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100245, encryptionId=a8fd10024527, topicName=预混胰岛素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2da517440382, createdName=xjy08, createdTime=Thu Jul 01 08:18:39 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601062, encodeId=7a4916010621b, content=<a href='/topic/show?id=dd43426460c' target=_blank style='color:#2F92EE;'>#复方制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42646, encryptionId=dd43426460c, topicName=复方制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=279318829047, createdName=chengjn, createdTime=Thu Jul 01 08:18:39 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622007, encodeId=c41d162200e2b, content=<a href='/topic/show?id=392480e970' target=_blank style='color:#2F92EE;'>#GLP-1RA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8079, encryptionId=392480e970, topicName=GLP-1RA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Jul 01 08:18:39 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623085, encodeId=36ad16230859a, content=<a href='/topic/show?id=2eb542152f0' target=_blank style='color:#2F92EE;'>#基础胰岛素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42152, encryptionId=2eb542152f0, topicName=基础胰岛素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51af20470990, createdName=liuyong2987, createdTime=Thu Jul 01 08:18:39 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978073, encodeId=85a19e80733e, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df324723890, createdName=452946589, createdTime=Tue Jun 29 23:48:57 CST 2021, time=2021-06-29, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=1658670, encodeId=5f5616586e09f, content=<a href='/topic/show?id=4b4d80e878' target=_blank style='color:#2F92EE;'>#GLP-1R#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8078, encryptionId=4b4d80e878, topicName=GLP-1R)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fea024898996, createdName=360611848, createdTime=Tue Dec 28 01:18:39 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1750233, encodeId=d68b1e502336d, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Fri Dec 17 22:18:39 CST 2021, time=2021-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949827, encodeId=55b2194982eb3, content=<a href='/topic/show?id=92ed443582b' target=_blank style='color:#2F92EE;'>#头对头#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44358, encryptionId=92ed443582b, topicName=头对头)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Fri Mar 04 23:18:39 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004437, encodeId=f6dd200443ead, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78621, encryptionId=54ebe8621cf, topicName=结果公布)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Mon Sep 13 11:18:39 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422759, encodeId=3d0e1422e593d, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8077, encryptionId=54fa80e701, topicName=GLP-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8f23732777, createdName=yibei, createdTime=Thu Jul 01 08:18:39 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587142, encodeId=c7b6158e14200, content=<a href='/topic/show?id=a8fd10024527' target=_blank style='color:#2F92EE;'>#预混胰岛素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100245, encryptionId=a8fd10024527, topicName=预混胰岛素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2da517440382, createdName=xjy08, createdTime=Thu Jul 01 08:18:39 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601062, encodeId=7a4916010621b, content=<a href='/topic/show?id=dd43426460c' target=_blank style='color:#2F92EE;'>#复方制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42646, encryptionId=dd43426460c, topicName=复方制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=279318829047, createdName=chengjn, createdTime=Thu Jul 01 08:18:39 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622007, encodeId=c41d162200e2b, content=<a href='/topic/show?id=392480e970' target=_blank style='color:#2F92EE;'>#GLP-1RA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8079, encryptionId=392480e970, topicName=GLP-1RA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Jul 01 08:18:39 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623085, encodeId=36ad16230859a, content=<a href='/topic/show?id=2eb542152f0' target=_blank style='color:#2F92EE;'>#基础胰岛素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42152, encryptionId=2eb542152f0, topicName=基础胰岛素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51af20470990, createdName=liuyong2987, createdTime=Thu Jul 01 08:18:39 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978073, encodeId=85a19e80733e, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df324723890, createdName=452946589, createdTime=Tue Jun 29 23:48:57 CST 2021, time=2021-06-29, status=1, ipAttribution=)]
    2021-06-29 452946589

    0

相关资讯

JAMA: 糖尿病患病率在过去20年持续上升,80%的患者血糖、血压和血脂控制不达标

该项研究分析了1999 到 2018 年美国成人糖尿病患病率变化趋势及美国成人糖尿病患者血糖、血压和血脂控制趋势,结果发现美国在过去20年间的糖尿病管理并不理想,得出糖尿病防控任务仍然非常艰巨。

NEJM:2型糖尿病治疗,Tirzepatide 优于索马鲁肽!

在 2 型糖尿病患者中,就糖化血红蛋白水平从基线到 40 周的平均变化而言,tirzepatide 不劣于并优于索马鲁肽。

JAMA 子刊:老年人可能会过度使用阿司匹林,尤其是糖尿病患者

阿司匹林,作为医药史上三大经典药物之一,自临床应用开始已有上百年的历史,至今依旧是解热、镇痛和抗炎药的良药。

Diabetes Care减肥是否成功主要靠脑:糖尿病患者通过低热量饮食和胃旁路手术减肥会导致不同的大脑激活模式

与通过限制卡路里减肥的人相比,接受减肥手术的人在食欲大脑处理方面经历了三种互补的变化。这些大脑对不同减肥方法的不同反应可能解释了为什么在完成短期VLCD后有重获体重的趋势。

JGH:低骨骼肌质量与2型糖尿病和 NAFLD 患者的肝纤维化有关

有研究报道,2型糖尿病 (T2D) 和低骨骼肌质量 (SMM) 与非酒精性脂肪肝 (NAFLD) 的风险增加有关。

Dig Dis Sci: 炎症性肠病合并糖尿病可预测不良疾病相关结果和感染并发症的发生

糖尿病 (DM) 和炎症性肠病 (IBD) 是与慢性炎症、生态失调、免疫功能受损和感染风险相关的慢性全身性疾病。DM 在改变 IBD 患者疾病活动方面的影响在